RT Journal Article
T1 Drug Repurposing for the Treatment of Bacterial and Fungal Infections.
A1 Miro-Canturri, Andrea
A1 Ayerbe-Algaba, Rafael
A1 Smani, Younes
K1 antimicrobial resistance
K1 bacteria
K1 fungi
K1 infection
K1 repurposing drug
AB Multidrug-resistant (MDR) pathogens pose a well-recognized global health threat that demands effective solutions; the situation is deemed a global priority by the World Health Organization and the European Centre for Disease Prevention and Control. Therefore, the development of new antimicrobial therapeutic strategies requires immediate attention to avoid the ten million deaths predicted to occur by 2050 as a result of MDR bacteria. The repurposing of drugs as therapeutic alternatives for infections has recently gained renewed interest. As drugs approved by the United States Food and Drug Administration, information about their pharmacological characteristics in preclinical and clinical trials is available. Therefore, the time and economic costs required to evaluate these drugs for other therapeutic applications, such as the treatment of bacterial and fungal infections, are mitigated. The goal of this review is to provide an overview of the scientific evidence on potential non-antimicrobial drugs targeting bacteria and fungi. In particular, we aim to: (i) list the approved drugs identified in drug screens as potential alternative treatments for infections caused by MDR pathogens; (ii) review their mechanisms of action against bacteria and fungi; and (iii) summarize the outcome of preclinical and clinical trials investigating approved drugs that target these pathogens.
PB Frontiers Research Foundation
SN 1664-302X
YR 2019
FD 2019-01-28
LK http://hdl.handle.net/10668/13548
UL http://hdl.handle.net/10668/13548
LA en
NO Miró-Canturri A, Ayerbe-Algaba R, Smani Y. Drug Repurposing for the Treatment of Bacterial and Fungal Infections. Front Microbiol. 2019 Jan 28;10:41. doi: 10.3389/fmicb.2019.00041. Erratum in: Front Microbiol. 2022 Feb 25;13:844615.
DS RISalud
RD Apr 19, 2025